News coverage about OraSure Technologies (NASDAQ:OSUR) has trended somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. OraSure Technologies earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 45.6923414332266 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Head to Head Review: OraSure Technologies (OSUR) versus Sientra (SIEN) (americanbankingnews.com)
- Quotidian Technical Highlights on Selected Medical Supplies Stocks … – PR Newswire (press release) (prnewswire.com)
- Quotidian Technical Highlights on Selected Medical Supplies Stocks — OraSure Technologies, Hill-Rom, Tandem Diabetes Care, and Mazor Robotics (bizjournals.com)
- Zacks: Analysts Anticipate OraSure Technologies, Inc. (OSUR) Will Post Quarterly Sales of $45.27 Million (americanbankingnews.com)
- OraSure Technologies, Inc. (OSUR) Given Average Recommendation of “Buy” by Analysts (americanbankingnews.com)
OraSure Technologies (NASDAQ:OSUR) opened at $18.19 on Monday. OraSure Technologies has a twelve month low of $8.39 and a twelve month high of $23.01. The stock has a market capitalization of $1,100.00, a PE ratio of 34.98, a P/E/G ratio of 3.49 and a beta of 1.28.
A number of research analysts recently issued reports on OSUR shares. Zacks Investment Research raised OraSure Technologies from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a report on Saturday, September 9th. Jefferies Group reaffirmed a “buy” rating and issued a $20.00 price target on shares of OraSure Technologies in a report on Tuesday, September 12th. Canaccord Genuity reaffirmed a “buy” rating and issued a $22.00 price target on shares of OraSure Technologies in a report on Tuesday, September 19th. Finally, ValuEngine cut OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $18.21.
In other news, Director Mara G. Aspinall acquired 5,000 shares of the stock in a transaction that occurred on Tuesday, November 7th. The stock was purchased at an average cost of $14.23 per share, for a total transaction of $71,150.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at $71,150. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Douglas A. Michels sold 22,923 shares of OraSure Technologies stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total value of $527,229.00. The disclosure for this sale can be found here. 6.40% of the stock is owned by company insiders.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
What are top analysts saying about OraSure Technologies? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OraSure Technologies and related companies.